



## **Study Enrollment Closure - STEER and STRENGTH**

**Dear SMA Community,**

We are pleased to share that enrollment is now complete for both STEER and STRENGTH, our investigational intrathecal (IT) OAV101 studies. These studies remain ongoing but are no longer recruiting new participants.

[STEER](#) is a Phase 3 study evaluating efficacy, safety, and tolerability of investigational intrathecal OAV101 in patients with type 2 SMA. STEER includes treatment naïve patients aged  $\geq 2$  to  $< 18$  years, able to sit, but who have never walked.

[STRENGTH](#) is a Phase 3b, open-label study evaluating safety, tolerability, and efficacy of investigational intrathecal OAV101 in patients aged 2 to  $< 18$  years with SMA after discontinuing treatment with nusinersen or risdiplam.

We appreciate the SMA community's support of this important research.

**With gratitude,  
YOUR NOVARTIS GENE THERAPIES TEAM**